Measuring Corneal Cells With Specular Microscopy
Specular Photomicrograpic Assessment of the Effect of Anti-VEGF Intravitreal Injections on Corneal Thickness and Endothelial Cell Density and Morphology
1 other identifier
observational
30
1 country
1
Brief Summary
Assess changes in the corneal cell count using Specular Microscopy following tretments with Anti-VEGF injections
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2012
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2012
CompletedFirst Submitted
Initial submission to the registry
February 11, 2013
CompletedFirst Posted
Study publicly available on registry
February 15, 2013
CompletedFebruary 15, 2013
February 1, 2013
3 months
February 11, 2013
February 12, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Specular Photomicrographic Assessment of the Effect of Anti-VEGF Intravitreal injections on corneal thickness and endothelial cell density and morphology
Changes in corneal endothelial cell density and corneal thickness measured by changes in pachymetry and corneal cell count.
Baseline, Month 6 and Month 12
Eligibility Criteria
Subjects of either gender with an age greater than 50 years of age who have been receiving intraocular Anti-VEGF medication every month for at least the past 3 months.
You may qualify if:
- Wet Age-related Macular Degeneration
- Receiving monthly intraocular injections of Anti-VEGF medication for at least 3 months
- Age greater than 50 years of age
You may not qualify if:
- experiences adverse events
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Retina Institute of Hawaii
Honolulu, Hawaii, 96815, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael D Bennett, MD
Retina Institute of Hawaii
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 11, 2013
First Posted
February 15, 2013
Study Start
August 1, 2012
Primary Completion
November 1, 2012
Study Completion
November 1, 2012
Last Updated
February 15, 2013
Record last verified: 2013-02